History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Standard
History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. / Minlikeeva, Albina N; Freudenheim, Jo L; Eng, Kevin H; Cannioto, Rikki A; Friel, Grace; Szender, J Brian; Segal, Brahm; Odunsi, Kunle; Mayor, Paul; Diergaarde, Brenda; Zsiros, Emese Z; Kelemen, Linda E; Köbel, Martin; Steed, Helen; deFazio, Anna; Jordan, Susan J; Fasching, Peter A; Beckmann, Matthias W; Risch, Harvey A; Rossing, Mary Anne; Doherty, Jennifer A; Chang-Claude, Jenny; Goodman, Marc T; Dörk, Thilo; Edwards, Robert; Modugno, Francesmary; Ness, Roberta B; Matsuo, Keitaro; Mizuno, Mika; Karlan, Beth Y; Goode, Ellen L; Kjær, Susanne K; Høgdall, Estrid; Schildkraut, Joellen M; Terry, Kathryn L; Cramer, Daniel W; Bandera, Elisa V; Paddock, Lisa E; Kiemeney, Lambertus A; Massuger, Leon F A G; Sutphen, Rebecca; Anton-Culver, Hoda; Ziogas, Argyrios; Menon, Usha; Gayther, Simon A; Ramus, Susan J; Gentry-Maharaj, Aleksandra; Pearce, Celeste L; Wu, Anna H; Kupryjanczyk, Jolanta; Jensen, Allan; Webb, Penelope M; Moysich, Kirsten B; Ovarian Cancer Association Consortium.
In: CANCER EPIDEM BIOMAR, Vol. 26, No. 9, 09.2017, p. 1470-1473.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
AU - Minlikeeva, Albina N
AU - Freudenheim, Jo L
AU - Eng, Kevin H
AU - Cannioto, Rikki A
AU - Friel, Grace
AU - Szender, J Brian
AU - Segal, Brahm
AU - Odunsi, Kunle
AU - Mayor, Paul
AU - Diergaarde, Brenda
AU - Zsiros, Emese Z
AU - Kelemen, Linda E
AU - Köbel, Martin
AU - Steed, Helen
AU - deFazio, Anna
AU - Jordan, Susan J
AU - Fasching, Peter A
AU - Beckmann, Matthias W
AU - Risch, Harvey A
AU - Rossing, Mary Anne
AU - Doherty, Jennifer A
AU - Chang-Claude, Jenny
AU - Goodman, Marc T
AU - Dörk, Thilo
AU - Edwards, Robert
AU - Modugno, Francesmary
AU - Ness, Roberta B
AU - Matsuo, Keitaro
AU - Mizuno, Mika
AU - Karlan, Beth Y
AU - Goode, Ellen L
AU - Kjær, Susanne K
AU - Høgdall, Estrid
AU - Schildkraut, Joellen M
AU - Terry, Kathryn L
AU - Cramer, Daniel W
AU - Bandera, Elisa V
AU - Paddock, Lisa E
AU - Kiemeney, Lambertus A
AU - Massuger, Leon F A G
AU - Sutphen, Rebecca
AU - Anton-Culver, Hoda
AU - Ziogas, Argyrios
AU - Menon, Usha
AU - Gayther, Simon A
AU - Ramus, Susan J
AU - Gentry-Maharaj, Aleksandra
AU - Pearce, Celeste L
AU - Wu, Anna H
AU - Kupryjanczyk, Jolanta
AU - Jensen, Allan
AU - Webb, Penelope M
AU - Moysich, Kirsten B
AU - Ovarian Cancer Association Consortium
N1 - ©2017 American Association for Cancer Research.
PY - 2017/9
Y1 - 2017/9
N2 - Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470-3. ©2017 AACR.
AB - Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.Methods: Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled HRs and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.Results: None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histologic subtype, weight status, age at diagnosis, or stage of disease (local/regional vs. advanced).Conclusions: Histories of endometriosis; asthma; depression; osteoporosis; and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.Impact: These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis. Cancer Epidemiol Biomarkers Prev; 26(9); 1470-3. ©2017 AACR.
KW - Journal Article
U2 - 10.1158/1055-9965.EPI-17-0367
DO - 10.1158/1055-9965.EPI-17-0367
M3 - SCORING: Journal article
C2 - 28864456
VL - 26
SP - 1470
EP - 1473
JO - CANCER EPIDEM BIOMAR
JF - CANCER EPIDEM BIOMAR
SN - 1055-9965
IS - 9
ER -
